For suspected loss of efficacy: Verify medication storage, handling, and injection technique Review adherence patterns and timing of doses Assess for other factors affecting treatment response (dietary changes, new medications, intercurrent illness) Consider dose optimization within approved ranges if not already at maximum dose Evaluate alternative explanations for treatment failure If treatment failure persists despite addressing these factors, options include: Switching to an alternative GLP-1 receptor agonist (semaglutide, dulaglutide) or other therapy For diabetes management: considering ADA-recommended alternatives such as metformin optimization, SGLT2 inhibitors, or basal insulin For weight management: exploring other FDA-approved anti-obesity medications Intensifying lifestyle interventions and behavioral support For suspected hypersensitivity reactions: Immediate discontinuation of tirzepatide is warranted for any signs of serious hypersensitivity, including urticaria, angioedema, difficulty breathing, or anaphylaxis

It includes the active form, dose, excipients, delivery system, manufacturing process, packaging and storage conditions
Dehydration, caloric restriction, and electrolyte shifts are named as common contributors, which is why it stresses hydration, electrolytes, and consistent meal timing
Judith Kimble (HHMI, University of WisconsinMadison), Dr
That single finding is what reassured the field that a triple agonist could be both potent and metabolically sensible